K'Watch Glucose: A ground-breaking biometric wearable for painless, minimally invasive and blood-free glucose monitoring.

Información del proyecto

KWatch Glucose

Identificador del acuerdo de subvención: 781100

DOI

10.3030/781100

Proyecto cerrado

Fecha de la firma de la CE 21 Julio 2017

Fecha de inicio 1 Agosto 2017

Fecha de finalización 30 Noviembre 2017

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

PK VITALITY
France

Periodic Reporting for period 1 - KWatch Glucose (K'Watch Glucose: A ground-breaking biometric wearable for painless, minimally invasive and blood-free glucose monitoring.)

Período documentado: 2017-08-01 hasta 2017-11-30

Resumen del contexto y de los objetivos generales del proyecto

Diabetes accounts for 12% of global health expenditure. 60M Europeans are affected by it and €90B are spent only in its treatment and hospitalization. Although 70M people globally should monitor their glucose, only 20% does. This is linked to the inconveniences that available self-monitoring devices pose to diabetics: several blood samples, painful, cumbersome, time-consuming, prone to infections, intricate use and stigmatizing.
We have developed K'Watch Glucose, a minimally invasive glucose self-monitoring system in a smart watch. Our innovative technology measures glucose levels from extracted interstitial fluid (ISF), without painful blood-sampling, high accuracy (>92%) and proven repeatability (30 days). Thanks to its small size, our solution stays “invisible” to others, enabling monitoring of glucose levels anytime and anywhere, without anyone noticing.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

In order to confirm the feasibility of our project, we have carried out a 4-month study focusing our effort on 3 main areas. Technically, we have studied the improvements needed and planned the work and scope of the optimization of the biochemical sensor system and the operative software and app as well as the clinical trial and an industrialization and scale-up plan. We have also prepared a complete Execution Plan for the development of K’Watch Glucose, including risk analysis and budget. Commercially, we have assessed the existing and new targeted markets, including the competition, to consolidate our marketing strategy. Moreover, an IPR analysis has been performed to ensure our Freedom-to-Operate. Finally, on the financial side, we have completed a financial forecast based on the marketing and price policy, to evaluate on a 5-year-projection.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

After Phase 2 project, we will introduce K’Watch in the European and North American Clinical-Grade wearables market in Q3 2020. We have estimated that the fifth year of commercialization, the sales of K’Watch Glucose and K’apsul will render revenues of €116,200M for PKvitality and the total profits will be €77,569M. With the introduction of K’Watch Glucose we will hire at least 139 new employees, including 25 for R&D, 7 in Customer Care and 80 as Salesforce and Marketing, as well as 24 for Administrative tasks.

image-1.png